Figure 3.

Co‐treatment with JQ1 and venetoclax affects the viability of ex vivo human CLL cells. A, Primary CLL cells were treated with JQ1 1 µmol/L, 0.5 µmol/L venetoclax alone or in combination for 72 h. The percent of non‐viable cells was determined by Annexin V staining and flow cytometry. B, upper panel: representative immunoblots of primary CLL cells treated with the indicated inhibitors for 72 h. Immunoblot analyses were conducted for the expression levels of BCL2 and vinculin in the cell lysates; lower panel: quantification of all analysed patients